However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has ...

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, ...

Eli Lilly and Co. (NYSE:LLY) on Wednesday released detailed findings from two late-stage obesity studies showing patients ...

Eli Lilly ( LLY +2.53%) has become the leader in a market marching toward the $100 billion mark. I'm talking about the weight ...

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates, as demand for its blockbuster ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the most impressive quarters in big pharma history, and the ...

ATTAIN-Maintain found oral orforglipron preserved prior loss after injection-to-oral transition, with only 0.9 kg regain from ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

By Chris Prentice NEW YORK, May 12 (Reuters) - Eli Lilly said on Tuesday that patients in a late-stage trial who had been ...

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on ...